Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here is one cash-producing company that leverages its financial strength to beat its competitors and two best left off your watchlist.

Two Stocks to Sell:

Callaway Golf Company (CALY)

Trailing 12-Month Free Cash Flow Margin: 8.6%

Formed between the merger of Callaway and Topgolf, Callaway Golf Company (NYSE: CALY) sells golf equipment and operates technology-driven golf entertainment venues.

Why Do We Think CALY Will Underperform?

1. Annual revenue growth of 17.1% over the last five years was below our standards for the consumer discretionary sector
2. Capital intensity will likely increase as its free cash flow margin is anticipated to drop by 3.2 percentage points over the next year
3. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

Callaway Golf Company’s stock price of $13.15 implies a valuation ratio of 27x forward P/E. Dive into our free research report to see why there are better opportunities than CALY.

Array (ARRY)

Trailing 12-Month Free Cash Flow Margin: 6.9%

Going public in October 2020, Array (NASDAQ: ARRY) is a global manufacturer of ground-mounting tracking systems for utility and distributed generation solar energy projects.

Why Is ARRY Risky?

1. Sales tumbled by 9.7% annually over the last two years, showing market trends are working against its favor during this cycle
2. Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
3. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value

At $7.30 per share, Array trades at 10.3x forward P/E. Read our free research report to see why you should think twice about including ARRY in your portfolio.

One Stock to Watch:

Vertex Pharmaceuticals (VRTX)

Trailing 12-Month Free Cash Flow Margin: 26.6%

Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ: VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.

Why Is VRTX Interesting?

1. Annual revenue growth of 14.1% over the last five years beat the sector average and underscores the unique value of its offerings
2. Strong free cash flow margin of 24.4% enables it to reinvest or return capital consistently
3. Industry-leading 40.4% return on capital demonstrates management’s skill in finding high-return investments

Vertex Pharmaceuticals is trading at $433.32 per share, or 23.7x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.